News Reader
02-04-2009, 05:29 PM
The U.S. Food and Drug Administration today announced that it is working with the maker of Xigris (drotrecogin alfa activated), Eli Lilly and Company, to further evaluate the incidence of serious bleeding events and death in patients who receive Xigris, a drug used to treat severe sepsis (a blood stream infection).
More... (http://www.fda.gov/bbs/topics/NEWS/2009/NEW01951.html)
More... (http://www.fda.gov/bbs/topics/NEWS/2009/NEW01951.html)